Some medical histories rule out a GLP-1 medication completely. India's 2025 ESI obesity guideline lists contraindications for each drug individually, and the absolute ones are consistent across all three GLP-1-based agents used for weight management.
All three agents, liraglutide 3 mg, semaglutide 2.4 mg, and tirzepatide, share the same absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
- Pregnancy or breastfeeding
- Prior serious hypersensitivity reaction to that specific drug
Medullary thyroid carcinoma and MEN2 are the hard line. If you, a parent, a sibling or a child have either, these drugs are excluded whatever your BMI, a restriction carried over from the Saxenda liraglutide label and mirrored for semaglutide and tirzepatide. Pregnancy and breastfeeding are also absolute. WHO's 2025 guideline recommends long-term obesity use in adults while explicitly excluding pregnant women. A prior serious allergic reaction to a given drug rules out that same drug.
Two further situations behave like contraindications even where a label stops short of the word. Type 1 diabetes and diabetic ketoacidosis are "not indicated" for these agents, so using them in place of insulin is unsafe off-label use. A confirmed episode of pancreatitis while on a GLP-1 is treated by South Asian expert consensus as a "stop and do not restart" event, which functions as a bar on future GLP-1 use even though the global labels frame it as a serious warning rather than a formal contraindication.